These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

423 related items for PubMed ID: 12668518

  • 1. Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: Studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptor blocker.
    Wang CH, Leung N, Lapointe N, Szeto L, Uffelman KD, Giacca A, Rouleau JL, Lewis GF.
    Circulation; 2003 Apr 15; 107(14):1923-9. PubMed ID: 12668518
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Enhancement of muscle glucose uptake by the vasopeptidase inhibitor, omapatrilat, is independent of insulin signaling and the AMP kinase pathway.
    Wong V, Szeto L, Uffelman K, Fantus IG, Lewis GF.
    J Endocrinol; 2006 Aug 15; 190(2):441-50. PubMed ID: 16899577
    [Abstract] [Full Text] [Related]

  • 4. The cardioprotective effect of dual metallopeptidase inhibition: respective roles of endogenous kinins and natriuretic peptides.
    Dumoulin MJ, Adam A, Burnett J, Heublein D, Yamaguchi N, Lamontagne D.
    Can J Physiol Pharmacol; 2005 Feb 15; 83(2):166-73. PubMed ID: 15791290
    [Abstract] [Full Text] [Related]

  • 5. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.
    Blais C, Fortin D, Rouleau JL, Molinaro G, Adam A.
    J Pharmacol Exp Ther; 2000 Nov 15; 295(2):621-6. PubMed ID: 11046097
    [Abstract] [Full Text] [Related]

  • 6. Effects of combined neutral endopeptidase 24-11 and angiotensin-converting enzyme inhibition on femoral vascular conductance in streptozotocin-induced diabetic rats.
    Arbin V, Claperon N, Fournié-Zaluski MC, Roques BP, Peyroux J.
    Br J Pharmacol; 2000 Jul 15; 130(6):1297-304. PubMed ID: 10903969
    [Abstract] [Full Text] [Related]

  • 7. The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors.
    Hartman JC.
    Ann Thorac Surg; 1995 Sep 15; 60(3):789-92. PubMed ID: 7545893
    [Abstract] [Full Text] [Related]

  • 8. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats.
    De Gennaro Colonna V, Rigamonti A, Fioretti S, Bonomo S, Manfredi B, Ferrario P, Bianchi M, Berti F, Muller EE, Rossoni G.
    Eur J Pharmacol; 2005 Jun 15; 516(3):253-9. PubMed ID: 15963975
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. ACE inhibition and glucose transport in insulinresistant muscle: roles of bradykinin and nitric oxide.
    Henriksen EJ, Jacob S, Kinnick TR, Youngblood EB, Schmit MB, Dietze GJ.
    Am J Physiol; 1999 Jul 15; 277(1):R332-6. PubMed ID: 10409290
    [Abstract] [Full Text] [Related]

  • 11. Changes in blood glucose and plasma insulin levels induced by bradykinin in anaesthetized rats.
    Damas J, Hallet C, Lefebvre PJ.
    Br J Pharmacol; 2001 Nov 15; 134(6):1312-8. PubMed ID: 11704652
    [Abstract] [Full Text] [Related]

  • 12. Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-converting enzyme inhibitors on bradykinin metabolism in the rat coronary bed.
    Dumoulin MJ, Adam A, Rouleau JL, Lamontagne D.
    J Cardiovasc Pharmacol; 2001 Apr 15; 37(4):359-66. PubMed ID: 11300648
    [Abstract] [Full Text] [Related]

  • 13. The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension.
    Seccia TM, Belloni AS, Guidolin D, Sticchi D, Nussdorfer GG, Pessina AC, Rossi GP.
    J Hypertens; 2006 Jul 15; 24(7):1419-27. PubMed ID: 16794493
    [Abstract] [Full Text] [Related]

  • 14. Angiotensin I-converting enzyme-dependent and neutral endopeptidase-dependent generation and degradation of angiotensin II contrarily modulate noradrenaline release: implications for vasopeptidase-inhibitor therapy?
    Raasch W, Dominiak P, Dendorfer A.
    J Hypertens; 2005 Aug 15; 23(8):1597-604. PubMed ID: 16003188
    [Abstract] [Full Text] [Related]

  • 15. Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent.
    Schäfer S, Schmidts HL, Bleich M, Busch AE, Linz W.
    Br J Pharmacol; 2004 Sep 15; 143(1):27-32. PubMed ID: 15289289
    [Abstract] [Full Text] [Related]

  • 16. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation.
    Farhy RD, Carretero OA, Ho KL, Scicli AG.
    Circ Res; 1993 Jun 15; 72(6):1202-10. PubMed ID: 7684331
    [Abstract] [Full Text] [Related]

  • 17. Renoprotective effects of omapatrilat are mediated partially by bradykinin.
    Zhou X, Ono H, Ono Y, Frohlich ED.
    Am J Nephrol; 2003 Jun 15; 23(4):214-21. PubMed ID: 12789027
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Synergy of amlodipine and angiotensin-converting enzyme inhibitors in regulating myocardial oxygen consumption in normal canine and failing human hearts.
    Mital S, Loke KE, Slater JP, Addonizio L, Gersony WM, Hintze TH.
    Am J Cardiol; 1999 Jun 17; 83(12A):92H-98H. PubMed ID: 10750596
    [Abstract] [Full Text] [Related]

  • 20. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats.
    Liu YH, Yang XP, Sharov VG, Sigmon DH, Sabbath HN, Carretero OA.
    Hypertension; 1996 Jan 17; 27(1):7-13. PubMed ID: 8591891
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.